Cancer Clinical Trials in Vandœuvre-lès-Nancy
48 recruitingVandœuvre-lès-Nancy, France
Showing 1–20 of 48 trials
Recruiting
Phase 2Phase 3
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial CancerBladder Cancer
Daiichi Sankyo630 enrolled79 locationsNCT07129993
Recruiting
Phase 3
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Biliary Tract Cancer
AstraZeneca1,100 enrolled168 locationsNCT07221253
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 1
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Triple-Negative Breast CancerColorectal, CancerSoft Tissue Sarcoma+3 more
Novartis Pharmaceuticals180 enrolled5 locationsNCT07261631
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Advanced Breast Cancer
MedSIR240 enrolled69 locationsNCT06382948
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 2
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals20 enrolled9 locationsNCT06004661
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting
Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup
NSCLC (Non-small Cell Lung Cancer)Oligometastatic Lung TumorSBRT
Institut du Cancer de Montpellier - Val d'Aurelle190 enrolled2 locationsNCT07441941
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled284 locationsNCT06252649
Recruiting
Phase 2
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
Institut Curie20 enrolled9 locationsNCT07193394
Recruiting
Not Applicable
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Breast Cancer
Institut Claudius Regaud120 enrolled25 locationsNCT05378204
Recruiting
Not Applicable
Guided Digital Self-Hypnosis Solution for Managing Hot Flashes in Patients Undergoing Adjuvant Hormone Therapy
Breast Cancer Female
Institut de Cancérologie de Lorraine76 enrolled1 locationNCT06552091
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Not Applicable
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Triple-Negative Breast CancerOvarian CancerCervical Cancer+3 more
Institut Curie1,050 enrolled6 locationsNCT03017573
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca1,800 enrolled409 locationsNCT06120491